Matches in Wikidata for { <http://www.wikidata.org/entity/Q79424830> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q79424830 description "artículu científicu espublizáu n'avientu de 2006" @default.
- Q79424830 description "im Dezember 2006 veröffentlichter wissenschaftlicher Artikel" @default.
- Q79424830 description "scientific article published on 01 December 2006" @default.
- Q79424830 description "wetenschappelijk artikel" @default.
- Q79424830 description "наукова стаття, опублікована в грудні 2006" @default.
- Q79424830 name "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascu" @default.
- Q79424830 name "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascu" @default.
- Q79424830 type Item @default.
- Q79424830 label "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascu" @default.
- Q79424830 label "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascu" @default.
- Q79424830 prefLabel "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascu" @default.
- Q79424830 prefLabel "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascu" @default.
- Q79424830 P1433 Q79424830-786AFF9C-C9E1-4E65-8C92-3BDF700B0F79 @default.
- Q79424830 P1476 Q79424830-5AA22CDD-0027-46EF-8F2D-267378DEAE56 @default.
- Q79424830 P2093 Q79424830-03A5B2C4-3E30-4D13-999B-3709F4E7C5F4 @default.
- Q79424830 P2093 Q79424830-0D221005-1871-4895-A3D5-64DD876DF7EC @default.
- Q79424830 P2093 Q79424830-5392391B-E836-4EB7-B2ED-9ED529688817 @default.
- Q79424830 P2093 Q79424830-8042B4B5-586C-4DA8-A0F9-C9A0C84AEFEC @default.
- Q79424830 P2093 Q79424830-95599D89-CEB9-4006-AD01-E200CDDCE05D @default.
- Q79424830 P2093 Q79424830-9C05EE84-96FF-4042-88BF-789AFAC0F27B @default.
- Q79424830 P304 Q79424830-D8019CC8-C47C-4860-8C0D-49A15E19D668 @default.
- Q79424830 P31 Q79424830-DEB8B248-D6D7-4DEC-8167-4B25179845D2 @default.
- Q79424830 P356 Q79424830-42ED99D5-A1DB-4F5A-A9CA-D33306CFB2CA @default.
- Q79424830 P407 Q79424830-F7F61D63-B9F9-4550-9B33-989B812AA1B5 @default.
- Q79424830 P433 Q79424830-76DBB45C-419A-4D1C-B412-FE64ED12C773 @default.
- Q79424830 P478 Q79424830-C3F257A6-FD4B-4705-926D-D83EDEA803E1 @default.
- Q79424830 P50 Q79424830-2BC7218F-1184-46E0-A7EF-B823E93D2164 @default.
- Q79424830 P50 Q79424830-F58FF669-7477-4DB0-B70D-ED357A282FDA @default.
- Q79424830 P577 Q79424830-DA7037BC-BD90-4213-9B63-AA1C434A7E5B @default.
- Q79424830 P698 Q79424830-953229F6-BCF0-4B04-B53B-5364453016D0 @default.
- Q79424830 P921 Q79424830-1F00B84A-D214-4935-80F3-7E3CF55DA940 @default.
- Q79424830 P921 Q79424830-37D3D23C-9F18-4BA0-BFCB-63A8E94B9D8B @default.
- Q79424830 P921 Q79424830-40CFAACA-25D0-42CF-A97D-AD22CAEA5361 @default.
- Q79424830 P356 J.AHJ.2006.07.022 @default.
- Q79424830 P698 17161053 @default.
- Q79424830 P1433 Q2227156 @default.
- Q79424830 P1476 "Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials" @default.
- Q79424830 P2093 "David J Frid" @default.
- Q79424830 P2093 "Michael Chen" @default.
- Q79424830 P2093 "Roman Poliszczuk" @default.
- Q79424830 P2093 "Sorin J Brener" @default.
- Q79424830 P2093 "Thomas B Ivanc" @default.
- Q79424830 P2093 "Tingfei Hu" @default.
- Q79424830 P304 "1059-1063" @default.
- Q79424830 P31 Q13442814 @default.
- Q79424830 P356 "10.1016/J.AHJ.2006.07.022" @default.
- Q79424830 P407 Q1860 @default.
- Q79424830 P433 "6" @default.
- Q79424830 P478 "152" @default.
- Q79424830 P50 Q108198403 @default.
- Q79424830 P50 Q7615086 @default.
- Q79424830 P577 "2006-12-01T00:00:00Z" @default.
- Q79424830 P698 "17161053" @default.
- Q79424830 P921 Q261327 @default.
- Q79424830 P921 Q422185 @default.
- Q79424830 P921 Q844935 @default.